These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6096264)

  • 1. [Mode of action and mechanisms of resistance of gyrase inhibitors].
    Dickgiesser N
    Immun Infekt; 1984 Nov; 12(6):298-302. PubMed ID: 6096264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine 5'-O-(3-thio)triphosphate (ATPgammaS) promotes positive supercoiling of DNA by T. maritima reverse gyrase.
    Jungblut SP; Klostermeier D
    J Mol Biol; 2007 Aug; 371(1):197-209. PubMed ID: 17560602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
    Heddle JG; Blance SJ; Zamble DB; Hollfelder F; Miller DA; Wentzell LM; Walsh CT; Maxwell A
    J Mol Biol; 2001 Apr; 307(5):1223-34. PubMed ID: 11292337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
    Jukič M; Ilaš J; Brvar M; Kikelj D; Cesar J; Anderluh M
    Eur J Med Chem; 2017 Jan; 125():500-514. PubMed ID: 27689732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA.
    Liu LF; Wang JC
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2098-102. PubMed ID: 276855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
    Basarab GS; Manchester JI; Bist S; Boriack-Sjodin PA; Dangel B; Illingworth R; Sherer BA; Sriram S; Uria-Nickelsen M; Eakin AE
    J Med Chem; 2013 Nov; 56(21):8712-35. PubMed ID: 24098982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
    Heddle JG; Lu T; Zhao X; Drlica K; Maxwell A
    J Mol Biol; 2001 Jun; 309(5):1219-31. PubMed ID: 11399091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 4.2 kDa synthetic peptide as a potential probe to evaluate the antibacterial activity of coumarin drugs.
    Scatigno AC; Garrido SS; Marchetto R
    J Pept Sci; 2004 Sep; 10(9):566-77. PubMed ID: 15473264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coumarins as inhibitors of bacterial DNA gyrase.
    Althaus IW; Dolak L; Reusser F
    J Antibiot (Tokyo); 1988 Mar; 41(3):373-6. PubMed ID: 2835349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
    Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbial DNA topoisomerases and their inhibition by antibiotics.
    Zimmer C; Störl K; Störl J
    J Basic Microbiol; 1990; 30(3):209-24. PubMed ID: 2164580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA supercoiling and relaxation by ATP-dependent DNA topoisomerases.
    Fisher LM; Austin CA; Hopewell R; Margerrison EE; Oram M; Patel S; Plummer K; Sng JH; Sreedharan S
    Philos Trans R Soc Lond B Biol Sci; 1992 Apr; 336(1276):83-91. PubMed ID: 1351300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the role of the latch in the positive supercoiling mechanism of reverse gyrase.
    Rodríguez AC
    Biochemistry; 2003 May; 42(20):5993-6004. PubMed ID: 12755601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
    Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
    J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.
    Heddle JG; Barnard FM; Wentzell LM; Maxwell A
    Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1249-64. PubMed ID: 11097055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR; Foster SR; Maxwell A
    J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.
    Sanyal G; Doig P
    Expert Opin Drug Discov; 2012 Apr; 7(4):327-39. PubMed ID: 22458504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.
    Brvar M; Perdih A; Renko M; Anderluh G; Turk D; Solmajer T
    J Med Chem; 2012 Jul; 55(14):6413-26. PubMed ID: 22731783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tus-mediated arrest of DNA replication in Escherichia coli is modulated by DNA supercoiling.
    Valjavec-Gratian M; Henderson TA; Hill TM
    Mol Microbiol; 2005 Nov; 58(3):758-73. PubMed ID: 16238625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex.
    Wentzell LM; Maxwell A
    J Mol Biol; 2000 Dec; 304(5):779-91. PubMed ID: 11124026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.